| Ident. | Authors (with country if any) | Title |
|---|
| 000127 (2017) |
Chi Wang Ip [Allemagne] ; Laura-Christin Klaus [Allemagne] ; Akua A. Karikari [Allemagne] ; Naomi P. Visanji ; Jonathan M. Brotchie ; Anthony E. Lang ; Jens Volkmann [Allemagne] ; James B. Koprich | AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease |
| 000138 (2016) |
Naomi P. Visanji [Canada] ; Jonathan M. Brotchie [Canada] ; Lorraine V. Kalia [Canada] ; James B. Koprich [Canada] ; Anurag Tandon [Canada] ; Joel C. Watts [Canada] ; Anthony E. Lang [Canada] | α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. |
| 000153 (2016) |
Qing He [République populaire de Chine] ; James B. Koprich [Canada] ; Ying Wang [République populaire de Chine] ; Wen-Bo Yu [République populaire de Chine] ; Bao-Guo Xiao [République populaire de Chine] ; Jonathan M. Brotchie [Canada] ; Jian Wang [République populaire de Chine] | Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease. |
| 000157 (2016) |
James B. Koprich [Canada] ; Tom H. Johnston [Canada] ; Gabriela Reyes [Canada] ; Vanessa Omana [Canada] ; Jonathan M. Brotchie [Canada] | Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque |
| 000551 (2015) |
Yilong Ma [États-Unis] ; Tom H. Johnston [Canada] ; Shichun Peng [États-Unis] ; Chuantao Zuo [République populaire de Chine] ; James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Yihui Guan [République populaire de Chine] ; David Eidelberg [États-Unis] ; Jonathan M. Brotchie [Canada] | Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET. |
| 000641 (2015) |
Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Monoamine Reuptake Inhibitors in Parkinson's Disease |
| 000719 (2015) |
Sujoy Phookan [États-Unis] ; Alexander C. Sutton [États-Unis] ; Ian Walling [États-Unis] ; Autumn Smith [États-Unis] ; Katherine A. O'Connor [États-Unis] ; Joannalee C. Campbell [États-Unis] ; Megan Calos [États-Unis] ; Wilson Yu [États-Unis] ; Julie G. Pilitsis [États-Unis] ; Jonathan M. Brotchie [Canada] ; Damian S. Shin [États-Unis] | Gap junction blockers attenuate beta oscillations and improve forelimb function in hemiparkinsonian rats. |
| 000877 (2014) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Katie D. Lewis [Australie] ; James B. Koprich [Canada] ; M Gabriela Reyes [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Jonathan M. Brotchie [Canada] | UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. |
| 000933 (2014) |
Sherri L. Thiele [Canada] ; Betty Chen [Canada] ; Charlotte Lo [Canada] ; Tracey S. Gertler [États-Unis] ; Ruth Warre [Canada] ; James D. Surmeier [États-Unis] ; Jonathan M. Brotchie [Canada] ; Joanne E. Nash [Canada] | Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models |
| 000C43 (2013) |
Philippe Huot [Canada] ; Tom H. Johnston ; James B. Koprich ; Susan H. Fox ; Jonathan M. Brotchie | The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. |
| 000C50 (2013) |
James B. Koprich [Canada] ; Philippe Huot ; Susan H. Fox ; Keith Jarvie ; Anthony E. Lang ; Philip Seeman ; Jonathan M. Brotchie | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. |
| 000E88 (2013) |
Lorraine V. Kalia [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials |
| 000F09 (2013) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tessa Snoeren [Pays-Bas] ; James B. Koprich [Canada] ; Michael P. Hill [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Use of catechol‐O‐methyltransferase inhibition to minimize L‐3,4‐dihydroxyphenylalanine‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned macaque |
| 000F36 (2013) |
Karen L. Eskow Jaunarajs [États-Unis] ; David G. Standaert [États-Unis] ; Tacey X. Viegas [États-Unis] ; Michael D. Bentley [États-Unis] ; Zhihao Fang [États-Unis] ; Bekir Dizman [États-Unis] ; Kunsang Yoon [États-Unis] ; Rebecca Weimer [États-Unis] ; Paula Ravenscroft [Canada] ; Tom H. Johnston [Canada] ; Michael P. Hill [Canada] ; Jonathan M. Brotchie [Canada] ; Randall W. Moreadith [États-Unis] | Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit |
| 001005 (2013) |
Alexander C. Sutton [États-Unis] ; Wilson Yu [États-Unis] ; Megan E. Calos [États-Unis] ; Lauren E. Mueller [États-Unis] ; Matthew Berk [États-Unis] ; Jenny Shim [États-Unis] ; Eric S. Molho [États-Unis] ; Jonathan M. Brotchie [Canada] ; Peter L. Carlen [Canada] ; Damian S. Shin [États-Unis] | Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat |
| 001038 (2013) |
James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada] | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques |
| 001116 (2012) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Michael N. Gandy [Australie] ; M. Gabriela Reyes [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Jonathan M. Brotchie [Canada] | The Monoamine Re-Uptake Inhibitor UWA-101 Improves Motor Fluctuations in the MPTP-Lesioned Common Marmoset |
| 001191 (2012) |
Philippe Huot [Canada] ; Tom H. Johnston ; James B. Koprich ; Ahmed Aman ; Susan H. Fox ; Jonathan M. Brotchie | L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. |
| 001293 (2012) |
Tom H. Johnston [Canada] ; Zak Millar ; Philippe Huot ; Keith Wagg ; Sherri Thiele ; Danielle Salomonczyk ; Christopher J. Yong-Kee ; Michael N. Gandy ; Matthew Mcildowie ; Katie D. Lewis ; Jordi Gomez-Ramirez ; Joohyung Lee ; Susan H. Fox ; Mathew Martin-Iverson ; Joanne E. Nash ; Matthew J. Piggott ; Jonathan M. Brotchie | A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates. |
| 001413 (2012) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Tayyeba Darr [Canada] ; Donna Pires [Canada] ; Lili-Naz Hazrati [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease |
| 001474 (2012) |
Olivier Rascol [France] ; Joaquim Ferreira [Portugal] ; Laurence Nègre-Pages [France] ; Santiago Perez-Lloret [France] ; Lucette Lacomblez [France] ; Monique Galitzky [France] ; Jean-Christophe Lemarié [France] ; Jean-Christophe Corvol [France] ; Jonathan M. Brotchie [Canada] ; Laura Bossi [France] | A proof‐of‐concept, randomized, placebo‐controlled, multiple cross‐overs (n‐of‐1) study of naftazone in Parkinson’s disease |
